A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention

Summary

Objective of the trial is to describe the efficacy and safety of satralizumab in patients with aquaporin-4 (AQP4) antibody seropositive NMOSD, either treatment naive or inadequate responders to previous treatment with rituximab (RTX) (or its biosimilar)

Timeline

Start

2022-08-02

Primary completion

2023-10-26

Completion

2023-10-26

Outcome

Outcome not reported

Stopped (Enrollment): “Study has proved infeasible to recruit in sufficient numbers. There are insufficient eligible patients presenting to sites.”

Drugs

Indications